Mass Balance Study of [14C]-Orvepitant Oral Solution in Healthy Male Subjects

Key Inclusion Criteria: * Healthy males * Aged 30 to 65 years inclusive at the time of signing informed consent. * Body mass index (BMI) of 18.0 to 35.0 kg/m2 as measured at screening. * Must provide written informed consent. * Must agree to adhere to the contraception requirements Key Exclusion Criteria: * History of any drug or alcohol abuse in the past 2 years. * Regular alcohol consumption \>21 units per week. * Current smokers and those who have smoked within the last 12 months. * Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. * Clinically significant abnormal clinical chemistry, haematology, or urinalysis as judged by the Investigator. * Subjects with a presence of any of the following at screening: bilirubin, alanine aminotransferase (ALT), or aspartate aminotransferase (AST) \>1.5 × the upper limit of normal. * Confirmed positive drugs of abuse test result. * Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results. * Evidence of renal impairment at screening, as indicated by an estimated creatinine clearance (CLcr) of \<80 mL/min using the Cockcroft-Gault equation. * History of clinically significant cardiovascular, renal, hepatic, chronic respiratory, or GI disease, neurological or psychiatric disorder, as judged by the Investigator.